RNS: RELEASE 25 June 2026
ImmuPharma PLC
("ImmuPharma" or the "Company")
2026 RESULT OF ANNUAL GENERAL MEETING
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that six of the six resolutions (Resolutions 1 - 6 inclusive) were duly passed by shareholders. Details are contained in the table below.
|
Resolution |
For |
% For |
Against |
% Against |
Withheld |
|
1. To receive the accounts of the Company for the year ended 31 December 2025 together with the reports thereon of the directors and auditors of the Company |
163,496,678 |
99 |
2,252,180 |
1 |
365,965 |
|
2. To re-appoint Ketan Patel as a director of the Company |
156,211,793 |
98 |
3,080,916 |
2 |
6,822,114 |
|
3. To re-appoint Crowe UK LLP as Auditor of the Company |
163,482,368 |
99 |
2,311,240 |
1 |
321,215 |
|
4. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting |
152,641,450 |
94 |
11,960,794 |
6 |
1,512,579 |
|
SPECIAL RESOLUTION 5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting |
151,322,867 |
93 |
13,507,185 |
7 |
1,284,771 |
|
SPECIAL RESOLUTION |
155,666,377 |
96 |
7,767,242 |
4 |
2,681,204 |
As at the date of the AGM, the number of issued ordinary shares of the Company was 623,911,379 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.
Ends
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptidebased therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.